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Abstract 
Malignant pleural mesothelioma (MPM) is an aggressive cancer most commonly caused by 
prior exposure to asbestos. Median survival is 12-18 months, since surgery is ineffective and 
chemotherapy offers minimal benefit. Preclinical models that faithfully recapitulate the 
genomic and histopathological features of cancer are critical for the development of new 
treatments. The most commonly used models of MPM are two-dimensional (2D) cell lines 
established from primary tumours or pleural fluid. While these have provided some important 
insights into MPM biology, these cell models have significant limitations. In order to address 
some of these limitations spheroids and microfluidic chips have more recently been used to 
investigate the role of the 3D environment in MPM. Efforts have also been made to develop 
animal models of MPM, including asbestos-induced murine tumour models, MPM-prone 
genetically modified mice, and patient derived xenografts (PDX). Here we discuss the 
available in vitro and in vivo models of MPM and highlight their strengths and limitations. We 
discuss how newer technologies, such as the tumour-derived organoids, might allow us to 
address the limitations of existing models and aid in the identification of effective treatments 
for this challenging to treat disease.  
Introduction 
Malignant pleural mesothelioma (MPM) is a relatively rare aggressive cancer[1]. It is most 
often caused through inhalation of asbestos fibres, although there is a long latency of more 
than 30 years between exposure and the development of disease[1]. Between 1994 to 2008, 
92,253 mesothelioma deaths were reported to the WHO, with the majority of cases being from 
Europe, and age-adjusted mortality rates increased at 5.37% per year[1]. Following the ban 
on importation and use of asbestos in many developed nations it is predicted that MPM death 
rates will fall in these nations between 2020-2040[2–5]. For example, in the UK, where the 
use of all types of asbestos was fully banned in 1999[6], the mesothelioma incidence rate is 
projected to fall by 53% between 2014 and 2035[7]. Yet, although asbestos use is prohibited 
in many countries, the industrialisation of developing nations is fuelling the use of asbestos 
and subsequently the incidence of MPM is expected to rise in the coming decades[8].    
MPM affects the mesothelial cells of the pleura and presents as three main histopathological 
subtypes (Table 1): polygonal “epithelioid” MPM is the most common subtype, representing 
60% of cases; spindle-shaped “sarcomatoid” MPM accounts for 10% of cases; and biphasic 
mesothelioma, consisting of a mixture of epithelioid and sarcomatoid cells, accounts for the 
remaining 30%[9,10]. Mesothelial markers used to identify MPM include calretinin, Wilms’ 
tumour gene product (WT-1), mesothelin, cytokeratin (CK) 5/6, HBME-1 antigen, 
thrombomodulin and podoplanin (D2-40)[10]. However, being less differentiated, many 
sarcomatoid MPM tumours only express CKs and a variable amount of calretinin, but gain 
expression of vimentin and smooth muscle markers[10]. The histopathological subtype as well 
as the stage of disease impacts overall survival with a diagnosis of epithelioid MPM being 
associated with the longest median survival (13.1 months) and sarcomatoid being associated 
with the worst survival (4 months)[11]. MPM also has great intra-tumour heterogenity which 
has been studied using a deconvolution approach which uncovered that all MPM tumours are 
comprised of combinations of epithelioid-like and sarcomatoid-like components but the 
proportions of each are highly associated with prognosis[12]. 
First line treatments that have been proposed for MPM include chemotherapy, surgery, 
radiotherapy, separately or in combination. Surgical procedures such as extrapleural 
pneumonectomy (EPP) and pleurectomy/decortication have been proposed as curative or 
palliative approaches respectively[13–15]. However, the clinical outcome of the mesothelioma 
and radical surgery (MARS) trial suggested that EPP within tri-modal therapy has no 
benefit[16]. The benefit of open pleurectomy/decortication in addition to chemotherapy is 
currently under investigation in the MARS 2 trial[17]. The MesoVATS trial previously showed 
that a video-assisted thoracoscopic partial pleurectomy does not improve overall survival of 
patients[18]. At present, the benefits of surgery in MPM remains limited. Radiotherapy 
primarily has a role in palliation, but has been suggested as an adjuvant to surgery and 
chemotherapy in multimodality treatment[13,15]. Combination chemotherapy with pemetrexed 
and cisplatin has remained unchanged as the standard of care since 2003 following a phase 
III clinical trial demonstrating superiority of the combination over cisplatin alone (median 
survival 13.3 months vs. 10 months)[19]. In 2016, a phase III trial of the anti-VEGF 
recombinant antibody, bevacizumab, in combination with standard chemotherapy was shown 
to increase survival in comparison to chemotherapy alone (18.8 months vs. 16.1 months) 
across all MPM subtypes[20]. This regimen would not be suitable for patients with 
cardiovascular comorbidities[20] and currently is not available due to lack of FDA, EMA and 
NICE registration and universal reimbursement[21,22]. A recent phase lll trial of combined PD-
1 inhibition, using nivolumab, and anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) 
monoclonal antibody ipilimumab, revealed prolonged overall survival compared to the 
standard chemotherapy regimen[23]. This drug combination which has been recently 
approved by FDA[24] showed more benefit for patients with non-epithelioid tumours[23], while 
non-epithelioid subtypes of MPM were less responsive to chemotherapy or surgery[25,26].  
Comprehensive analysis of MPM samples has revealed the genomic landscape of this 
disease. A key finding has been that the disease is dominated by loss of function mutations in 
a number of tumour suppressor genes including: 1. cyclin-dependent kinase inhibitor 2A 
(CDKN2A, alias for INK4A/ARF) with homozygous deletion in 45-49% of cases, encodes two 
alternative reading frame proteins p14ARF and p16INK4A (involved in the p53 and retinoblastoma 
protein (RB1) pathways); 2. BRCA associated protein 1 (BAP1) mutations are observed in 22-
57% of cases, encodes a tumour suppressor that regulates several processes including the 
cell cycle, cell death and the response to DNA damage;  3. neurofibromin 2 (NF2) is mutated 
in 19-50% of cases, encodes Merlin which is involved in the inactivation of the receptor-
dependent mitogenic signalling pathway, inhibition of PI3K activity and regulation of the hippo 
pathway[27–40]. In addition, TP53 mutations has been reported in 4-20% of 
cases[34,37,41,42]. CDKN2B (alias for INK4B), which is adjacent to CDKN2A and encodes 
p15INK4b also recurrently shows loss of copy number[33,34,43]. In the COSMIC database, 
recurrent mutations have also been found in a further set of genes including PTEN and 
RB1[34]. Comparisons of mutational profiles in the various MPM subtypes reveals common 
and exclusive mutations. Genetic alterations in CDKN2A, BAP1 and NF2 are common in all 
subtypes with higher frequency of BAP1 and NF2 in epithelioid and sarcomatoid 
respectively[34]. Other significantly mutated genes include SETD2, LATS1, LATS2, CDKN2B, 
MST1 and MTOR[34]. While genetic alterations in STK3, DDX3X, DDX51, SETD5, SF3B1 
and TRAF7 were exclusively detected in epithelioid and biphasic disease, genetic alterations 
in SETDB1, TP53, TSC2, ULK2 and SAV1 were found only in sarcomatoid and biphasic 
disease[34]. Notably, TP53 mutations were associated with a lower survival rate[34]. 
Furthermore, classification of biphasic subtype to epithelioid like (biphasic-E) and sarcomatoid 
like (biphasic-S) based on RNA-sequencing, found genetic alterations in STK3 and DDX51 
only in biphasic-E and TSC2 only in biphasic-S[34] (Table 1).  
Conversely, there are few activating oncogenic driver genes or protein-altering mutations in 
MPM compared with other solid tumours[34,37]. This unfortunately limits the number of 
available cancer-selective drug targets since existing drugs mostly target activating 
oncogenes. Nevertheless, studies of the fundamental biology of MPM have yielded potential 
novel targeted therapies that are currently being tested in clinical trials, including inhibitors of 
histone methyltransferase EZH2, focal adhesion kinase (FAK), mesothelin, PI3K, mTOR, PD-
1 and PD-L1, and anti-angiogenic therapies such as VEGF inhibitors[44,45]. Unfortunately, 
many clinical trials in MPM have proved negative[44,45]. This may reflect the availability of 
drug resistance pathways to MPM tumours. Furthermore, the lack of biological biomarkers for 
responsiveness to most targeted therapies has precluded patient stratification and 
consequently clinical responses restricted to small patient cohorts might conceivably have 
been missed. However, careful patient selection might improve drug-responsiveness, as 
suggested by a recent phase lla trial of a poly ADP ribose polymerase (PARP) inhibitor, 
rucaparib, which demonstrated efficacy in patients with BAP1/BRCA1 deficient malignant 
mesothelioma[46].   
The development of new therapeutic approaches for MPM requires a larger and more diverse 
panel of preclinical MPM models to recapitulate the patient population both genomically and 
histopathologically as well as the ability to model relevant drug response. Consequently, much 
effort has been invested in establishing 2D cell lines (cells grown as flat 2D cultures) from 
primary MPM tumours and pleural effusions[47,48]. More complex 3D in vitro models and a 
number of murine in vivo models have also been developed. Here, we discuss the available 
in vitro and in vivo preclinical MPM models, highlighting both their strengths and limitations, 
and the gaps that remain to be filled by improved models.  
2D culture of human pleural mesothelioma cells 
Many human MPM cell lines have been established from tumour tissue and pleural 
effusions[48–70] with success rates ranging from 20% to 84%[54,64,68,70] (Supplementary 
Table 1). These cell lines represent a spectrum of MPM histopathological subtypes and many 
harbour the genetic aberrations commonly observed in MPM tumours, including inactivation 
of NF2, CDKN2A and BAP1 genes[31,39,42,58,71,72]. However, most studies have not 
compared cell lines to the original tumour from which they were derived to determine how well 
they recapitulate the genomic and histopathological features. To date, such a comparison has 
only been conducted once and concordance of genomic alterations was found to be high 
between the tumour and early passage cell lines, although some single nucleotide variants 
(SNV) were found exclusively in the cell lines[49]. This could represent the expansion of a rare 
clone present in the tumour or acquisition of new SNVs during in vitro culture. Furthermore, in 
order to facilitate mesothelioma diagnosis, using a large panel of 61 mesothelioma cell lines 
from pleural effusions[73], a genome-wide analysis has been conducted. As a result, it was 
showed that the genes COL3A1, SLPI, ITLN1, and CCL2 are expressed preferentially in MPM 
cells when compared to lung adenocarcinomas[73]. Accordingly, significantly higher levels of 
secreted CCL2 were found in pleural effusions of MPM patients compared with pleural fluid 
from patients with other metastatic cancers or benign conditions[73]. 
The majority of available malignant cell lines can be passaged indefinitely. As such, genomic 
instability, including polyploidy[74], copy number alterations and the emergence of new 
aberrations[58,75] have been observed following long-term culture of MPM models. Moreover, 
kataegis, the accumulation of a large number of single nucleotide substitutions clustered in a 
single locus was reported in MPM cell cultures but not primary tumour tissue[49]. It has also 
been shown recently that newly derived primary mesothelioma cells display a significantly 
different transcriptome compared with established MPM cell lines[48]. Furthermore, long-term 
culturing of primary MPM cells can affect their response to drugs[76]. Therefore, as cell lines 
adapt to 2D culture they lose many of the characteristics of the original tumour which can 
affect their use in research. 
It has recently been demonstrated that cell lines represent only part of the sub-clonal diversity 
of primary tumours and that different sub-clones may be dominant in the mesothelioma 
tumours and derived cell lines[49]. In line with this, some groups reported the development of 
two morphologically distant MPM cell lines obtained from the same patient, with differential 
expression of genes and chromosomal aberrations[56,65]. Therefore, cell lines fail to 
recapitulate the complete tumour heterogeneity found in patient tumours.  
Early passage, primary MPM cell lines have been exploited in a number of transcriptomic 
analyses, supporting the identification of putative diagnostic markers and treatment avenues. 
A recent transcriptomic analysis of a collection of primary MPM cultures, generated in the 
1990s from patient samples obtained from French hospitals[77,78] led to the identification of 
distinct molecular subgroups of MPM with divergent prognoses. The observed differences 
could be attributed largely to the varying mutation profiles between subtypes as well as 
divergent deregulated pathways, including epithelial to mesenchymal transition and TGF 
signalling[79]. The molecular subtypes of MPM can also be predicted based on the differential 
expression of PPL, UPK3B and TFP1 genes[79]. However, none of these studies have been 
translated to new diagnostic tools nor treatments for MPM. 
Early passage MPM cell lines have been also used in drug sensitivity testing in a number of 
studies[58,76,80–82], demonstrating variability in drug response between individuals and 
indicates the importance of personalized medicine. Integration of drug sensitivity testing of 
eighty-one short-term primary mesothelioma cell cultures with gene expression data revealed 
three response groups corresponding to distinct gene signatures involving the FGF signalling 
pathway[80]. High-throughput drug sensitivity testing of a panel of commercial and primary 
early-passage mesothelioma cell lines identified a subgroup of MPM lines highly sensitive to 
FGFR inhibition as well as death receptor agonist tumour necrosis factor-related apoptosis-
inducing ligand (TRAIL), associated with BAP1 loss[81,82].  A phase Ib clinical trial of a FGF 
ligand trap in combination with pemetrexed/cisplatin chemotherapy appeared to show durable 
responses[83] but further validation is required before loss of BAP1 can be used as a 
biomarker for responsiveness to FGF/FGFR inhibitors or TRAIL.    
Patient-derived mesothelioma cell lines therefore represent a simple model with which to study 
MPM biology and sensitivity to therapeutics. However, enthusiasm for their use in guiding 
personalised medicine must be tempered by important limitations: (i) their proclivity to adapt 
to 2D culture conditions thereby changing their phenotype, (ii) their failure to recapitulate 
tumour heterogeneity, and (iii) the lack of immune and stromal cell interactions in culture 
conditions.  
Animal models 
Animal models offer the ability to capture some of the complexity of the in vivo tumour 
environment that is known to contribute to disease progression and drug responsiveness. One 
major issue of animal models is the time and cost associated with them and subsequently 
making them unsuitable for large-scale phenotypic screens. Yet, such models are essential 
for drug testing and have substantially contributed to our understanding of MPM[84]. Several 
groups have generated MPM animal models including genetically modified mice, asbestos-
induced murine models, as well as PDX models (Table 2).  
Genetically engineered mouse models 
MPM mouse models have been established through the alteration of genes known to be 
involved in human MPM. Mice with mesothelial-specific deletion of Nf2, p53, and Ink4a/Arf 
were generated using intra-thoracic injection of Adeno-Cre virus in homozygous and 
heterozygous conditional knockout (CKO) mice of Nf2;p53, Nf2;Ink4a/Arf and Nf2;p53 carrying 
an inactive Ink4a allele (Nf2;p53;Ink4a*)[85]. Conditional Nf2;Ink4a/Arf mice demonstrated 
increased pleural invasion compared to conditional Nf2;p53 mice[85]. Furthermore, 
homozygous CKO mice Nf2;p53;Ink4a* were highly malignant with invasion in 75% of tumours 
in both parietal and visceral pleura and had the worst survival with a median survival of around 
11 weeks compared with the other homozygous CKO mice (around 19 and 31 weeks in 
Nf2;p53, Nf2;Ink4a/Arf respectively). These indicate that Ink4a loss leads to a more aggressive 
phenotype and poor clinical outcome of MPM[85]. Immunohistochemistry of the murine 
mesotheliomas identified the epithelioid MPM phenotype in the CKO mice Nf2;p53 and Nf2; 
Ink4a/Arf mice, but not in Nf2;p53;Ink4a* mice. Sarcomatoid phenotypes were found in all 
CKO mice[85]. In this manner, by inactivating genes known to be mutated frequently in 
mesothelioma, a powerful model was generated that (i) yielded high incidence of spontaneous 
mesothelioma development and (ii) gave a short latency for tumour initiation. However, in 
humans with MPM, it is the epithelioid histological subtype that predominates, while most CKO 
mice developed sarcomatoid MPM. Only when CKO mice of Nf2;p53; Ink4a/Arf were exposed 
to asbestos using intrapleural injection, the tumours demonstrated predominantly epithelioid 
subtype[86]. Furthermore, in contrast to the reported rarity of p53 mutations in human 
epithelioid MPM, CKO mice of Nf2;p53 developed epithelioid MPM. This might reflect species 
differences with respect to the impact of these genes or relate to different oncogenic 
mechanisms, such as the prolonged effects of asbestos fibres in human patients versus acute 
onset of somatic mutations in mice[85].   
Murine models have been generated by conditional knockout in the pleura, of various 
combinations of the genes most frequently altered in human MPM: Bap1, Ink4a/Arf and 
Nf2[87]. Homozygous deletion of each individual gene led to few or no malignant 
mesotheliomas of the pleura or peritoneum[87].  Mesotheliomas were observed following 
homozygous co-deletion of Bap1;Nf2, Bap1;Ink4a/Arf and Nf2;Ink4a/Arf in 17%, 22% and 63% 
of mice respectively, rising to 85% of mice in which all three genes were targeted[87]. The 
partial penetrance of MPM in all allelic combinations suggests partial redundancy amongst 
these tumour suppressors and that additional events are required to drive the phenotype. The 
median survival of Nf2;Ink4a/Arf mice was reproducibly around 27-35 weeks in different 
studies[85,87,88] (Table 2).  The triple CKO mice had a shorter latency (12 to 16 weeks) 
compared to double CKO mice (21 to 40 weeks)[87,88]. Similarly, triple homozygous CKO 
Bap1;Nf2;Ink4b/Ink4a/Arf  mice also have a short median survival of 12 weeks and display 
features similar to those of human MPMs including activation of the PI3K and MAPK pathways, 
substantial macrophage infiltration and the presence of a significant number of T cells, B cells 
and natural killer cells[88]. RNA sequencing revealed malignant mesotheliomas in the triple 
CKO mice compared to double CKO of Nf2;Ink4a/Arf were enriched in transcripts of genes 
controlled by polycomb repressive complex 2 (PRC2) including cancer related genes[87]. This 
argues that loss of BAP1, which forms part of a polycomb repressive deubiquitinase 
complex[27], contributes to tumour progression by loss of PRC2-mediated repression of 
oncogenic genes[87]. Consequently, these CKO mice are potential models to test therapeutics 
in these various genetic backgrounds. However, variability in the subtypes of tumours resulting 
from the same double and triple CKO mice in different studies may complicate interpretation 
of these results, with non-epithelioid subtypes in one study[87] and all three histological 
subtypes in others[85,88] (Table 2).  
Given that PI3K signalling pathway appears hyper-activated in many human MPMs, when it 
should normally be antagonised by PTEN, a mouse model was generated by inactivation of 
Pten and Tp53 in the mesothelium[89]. Both peritoneal and pleural malignant mesotheliomas 
developed in these double KO mice, while Pten inactivation alone was not sufficient for tumour 
development[89]. Most of the mesotheliomas were non-epithelioid, which is consistent with 
the low PTEN levels observed in human sarcomatoid tumours and with the association of 
Tp53 mutations with non-epithelioid subtypes[89,90]. This model was associated with 
MEK/ERK and PI3K activation and, accordingly, inhibition of MEK and PI3K using Selumetinib 
and AZD8186 increased the survival of Pten;p53 mice[90]. Although the Pten;p53 mice 
provide a relevant preclinical model for mesothelioma with sarcomatoid features, the common 
somatic genetic alterations found in human MPM are not recapitulated in this model[89].  
Asbestos/Asbestos-like induced murine models 
Malignant mesothelioma can also be induced through murine exposure to asbestos fibres. 
Peritoneal mesothelioma is even rarer than MPM, perhaps because less asbestos reaches 
the human peritoneum or this might reflect a different mode of pathogenesis entirely. However, 
most asbestos-induced murine models have been developed by intraperitoneal injection of 
asbestos and subsequent  investigation of extracted mesothelial cells from malignant ascites 
that formed within the model[42,91–97]. One reason for this experimental approach is that 
asbestos exposure by inhalation, which is more physiologically relevant to how MPM develops 
in humans, results in low pleural tumour burden in murine models[94]. Several studies 
demonstrated that inactivation of Bap1, Nf2, Ink4a/Arf and Tp53 led to a higher incidence and 
rapid progression of malignant mesothelioma in comparison to the wildtype mice treated with 
asbestos[42,91–95,98].  
Carbon nanotubes (CNT), which share some physical characteristics with asbestos, are 
increasingly used in medical and commercial applications[99]. Trans-tracheal intrapulmonary 
delivery of multiwalled CNTs in rats induces pleural and pericardial mesothelioma in 16% of 
rats between 24-27 months[100]. Similarly, in wildtype mice injection of long fibre CNTs into 
the pleural cavities causes pleural mesothelioma in 10-25% of animals compared with 9% of 
mice injected with asbestos[99]. Progression of murine mesothelioma lesions induced by CNT 
and asbestos were associated with increased cell proliferation and oxidative damage[99]. In 
this model, hypermethylation of the Ink4a/Arf locus before tumour development caused loss 
of p19Arf  (homologue to human p14ARF) and p16Ink4a protein and led to deletion of Arf in end 
stage mesothelioma, recapitulating an epigenetic feature of human MPM[99]. The long latency 
of this model is both its strength and its main weakness. On one hand, it provides a valuable 
tool to study molecular events that occur during the latency period, such as the 
hypermethylation causing loss of p19Arf, but equally the time required to develop tumours (up 
to 20 months), make it unsuitable for drug testing. In addition to these issues, the rat model 
has yet to be characterised extensively at a molecular level.   
Graft models 
Subcutaneous or intrathoracic injection of human MPM cell lines into mice are frequently used 
to study mesothelioma biology and treatment strategies[101–104]. Highly passaged human 
mesothelioma cell lines lack many characteristics of their original tumours and, importantly, 
generate little of the intra-tumour heterogeneity that is typical of the human disease. To date, 
there are few studies generating xenografts directly from human MPM tumour tissue or pleural 
fluid. In one study, subcutaneous xenografts were generated from early passage (below 
passage 5) primary mesothelioma cultures, derived from the pleural fluid of four patients with 
MPM and the ascitic fluid of one patient with peritoneal mesothelioma[105]. A larger bank of 
xenograft models was established through subcutaneous implantation of fresh tumour 
material from 50 MPM patients with an engraftment rate of 40% and were subsequently 
passaged up to 5 generations[106]. These xenografts maintained the expression of markers 
of the primary cells including Mesothelin, Calretinin, WT1 and BAP1[105] and the histological 
subtype of epithelioid and sarcomatoid in the original tissue[106]. However, some of biphasic 
tumours gave rise to xenografts with either epithelioid or sarcomatoid histology only[106]. 
While most sarcomatoid and biphasic samples formed xenografts, only one third of epithelioid 
samples engrafted successfully and interestingly they were from patients with a poorer 
outcome[106]. This limits xenograft models largely to the study of more aggressive forms of 
MPM. Treatment of a subset of the models across different histological subtypes with cisplatin 
inhibited growth of 7 of 10 tested PDXs; however, pemetrexed, either alone or in combination 
with cisplatin, did not affect the growth of these xenografts owing to the metabolism of folate 
by NOD/SCID mice, which differs from that in humans[106]. Furthermore, engrafting the 
tumour from pleural mesothelium into subcutaneous tissue profoundly changes the tumour 
microenvironment. Finally, although PDX models are a valuable tool to assess the response 
of patients to specific treatments, the lack of an immune system limits their utility for testing 
immunotherapies.  
To evaluate immunotherapies for mesothelioma, syngeneic murine models can be used[107–
110]. In these models, murine cell lines are implanted into the immunocompetent host, for 
example subcutaneous or intraperitoneal injection of murine mesothelioma cells including: 
AB1, AB12, AB22 cells in BALB/c mice; AE17 cells in C57BL/6J mice; and F4-T2, F5-T1, M5-
T1 cells in F344 Fischer rats[107–115]. Very few studies have used direct implantation of 
murine mesothelioma lines into the pleural space of mice[114]. In addition, all these murine 
mesothelioma cell lines were in fact established from peritoneal mesothelioma following 
intraperitoneal injection of asbestos[108,113,116]. While peritoneal and pleural mesothelioma 
might share some of the same biology, this has yet to be proved. In addition, similar to most 
available human MPM lines, murine mesothelioma cell lines suffer from having undergone 
clonal selection leading to adaptation to in vitro culture. Also, as with human cell lines, murine 
syngeneic tumour models fail to reproduce the intra-tumour and inter-patient heterogeneity 
seen in the clinic.  
3D models  
Spheroids: Several groups have cultured established mesothelioma cell lines or primary 
tumour tissue fragments in non- or low-adherent conditions leading to the formation of 3D 
structures called cancer spheroids. These have been used to study the biology of 
mesothelioma and test drugs[61,117–120](Figure 1a). Spheroid cultures recapitulate the 
resistance of mesothelioma cells to apoptosis more effectively than 2D cultures[117,121–124]. 
This may reflect the very different transcriptional profiles that 2D versus spheroid culture 
conditions generate for the same lines[125,126]. Indeed, genes involved in apoptosis are 
downregulated in spheroids[125]. Although 3D cultures are likely to be an improvement upon 
classical 2D conditions, spheroids derived from cell lines will suffer many of the same 
limitations as 2D cultures, such as their lack of heterogeneity. By contrast, tumour-derived 
spheroids may overcome this and be maintained in culture for months. A single report of 
mesothelioma spheroids grown in vitro describes the retention of a proliferation rate similar to 
that of the original tumour for four weeks[120]. Unfortunately, there are currently no long-term 
spheroid models that permit expansion of cell number, which limits the range and number of 
experiments that can be conducted.  Moreover, no studies have yet compared the genomic 
stability of MPM spheroids and their concordance with the original tumour.  
Tumour on a chip: Microfluidic chips offer another method to model the 3D geometrical shape 
and the dynamic microenvironment by providing a perfused system mimicking a vascularised 
tumour[127]. These devices have been used to develop a 3D model of MPM using either 
tumour biopsies directly from patients or spheroids derived from cell lines[127,128] (Figure 
1b). Although this system has demonstrated potential to predict clinical response to 
chemotherapy, applicability to long-term culture or indeed systematic drug screening are likely 
to be challenging. 
Outlook 
There has been a disappointing lack of progress in the treatments available for MPM patients 
and global incidence rates are set to increase. Many clinical trials have been conducted, often 
based on the results of experiments using simple preclinical models, but they have not 
translated from model to patient. This suggests that the current preclinical MPM models are 
not recapitulating human physiology sufficiently well and/or we lack enough models to capture 
the diversity of the disease. High-quality preclinical models are essential for the development 
of new treatments for this lethal cancer. Cell lines, spheroids and animal models each have 
their individual strengths and limitations, so no single model possesses every ideal feature. It 
is therefore essential that the choice of model is driven by the aim of a given study.  
There has been great interest in the recent development of a 3D cell model technology called 
organoids[129] which have overcome many limitations of preclinical models. Organoids are 
grown in a 3D matrix such as basement membrane extract (BME) or Matrigel, enriched for 
laminins and collagens to resemble the basement membrane[129,130] (Figure 1c). Unlike 
spheroids, organoids can be propagated for long periods in culture using defined media[129] 
making them feasible to biobank and to be an accessible resource. There are now organoid 
derivation protocols for many epithelial tissues and cancers including pancreas, colon, 
oesophagus, ovary, breast, prostate, endometrium, liver, and lung[129–138]. These studies 
have demonstrated how these models can be generated at relatively high success rates (70 
to more than 90%) and importantly recapitulate genomic alterations and histopathological 
features of the tumour of origin as well as a degree of the subclonal architecture present in 
the tumour[129–138]. They are amenable to a number of experimental techniques including 
medium-throughput drug sensitivity testing[130,139] and importantly have been shown to 
recapitulate patient responses to chemotherapy as well as other anti-cancer agents in the 
setting of co-clinical trials or a prospective clinical study[140,141]. Furthermore, methods have 
been developed that enable the successful co-culture of  organoids with other cell types found 
in the tumour microenvironmant, such as immune and stromal cells, increasing the complexity 
of organoids culture to better recapitulate the tumour microenvironment[142–146]. Large scale 
efforts, such as Human Cancer Models Initiative, are now attempting to derive and 
characterise panels of cancer organoids that recapitulate the diversity of patient population 
and to make these models available to the community in order to identify new therapeutic 
strategies for a variety of cancer types. Unfortunately, to date organoid technology has not 
been applied to MPM. The development of MPM organoids to provide a strong tool with which 
to study MPM represents a significant hope for the future. 
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Table 1: Characteristics of MPM subtypes 
Subtype Morphology Markers Prognosis 
(Months) 
Genetic Alteration+ 






13.1  CDKN2A, BAP1, NF2, 
SETD2, LATS1, LATS2, 
CDKN2B, MST1, 
MTOR, STK3, DDX3X, 





only CKs,  
Calretinin, 
vimentin and 
Smooth muscle  
4  CDKN2A, BAP1, NF2, 
SETD2, LATS1, LATS2, 
CDKN2B, MST1, 
MTOR, SETDB1, TP53, 
TSC2, ULK2 and SAV1. 
Biphasic-E Mixed Mixed 8.4 CDKN2A, BAP1, NF2, 
SETD2, LATS1, LATS2, 
CDKN2B, MST1, 
MTOR, TSC1, STK3, 
DDX3X, DDX51, 
SETD5, SF3B1, TRAF7, 
SETDB1, TP53, ULK2 
and SAV1 
Biphasic-S CDKN2A, BAP1, NF2, 
SETD2, LATS1, LATS2, 
CDKN2B, MST1, 
MTOR, DDX3X, SETD5, 
SF3B1, TRAF7, 
SETDB1, TP53, TSC1, 
TSC2, ULK2 and SAV1 
Ref [9,10] [10] [11] [34] 
 
+Subtypes for genetic alterations refer to the molecular classification based on RNA-
sequencing data 
 
Table 2. List of Animal Models of MPM  
Animal Model Method (if 
applicable) 
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- All subtypes 85.5% 19.3 [85] 
Nf2;p53  
(het, hom) 

















- All subtypes 34.1% 58.6 
Nf2;Ink4a/Arf 
(hom, het) 
- All subtypes 34.6% 70.7 
Nf2;p53;Ink4a* 




































17% 21 [87] 



























- NA 75% 27.1 [88] 
Bap1; NF2; 
Ink4b/Ink4a/Arf  
(hom, hom, hom)  
- NA NA 12.1 
Bap1; NF2; 
Ink4b/Ink4a/Arf   
(het, hom, hom) 














































Subcutaneous - 50 All subtypes - - [106] 
Subcutaneous - 4 Epithelioid - - [105] 
++The numbers indicate thoracic tumours including MPM, rhabdomyosarcomas, and schwannomas 
hom: homozygous; het: heterozygous. 
  
Figure 1. Current and potential future 3D models of MPM. a) Spheroids are obtained by 
culturing the cell lines or dissected primary tissues as small as 1 mm on a non or low-
adherent plate.  b) Microfluidic chips are implemented to model MPM using cell line derived 
spheroids or digested tumour tissue from patients. Arrows shows the medium flow. C) 
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Supplementary Table 1. List of human pleural mesothelioma cell lines with characterised 
histological and genetic background. 
 
Cell line  Origin Histology/Morphology Genetic alterations Ref 
MM1 tumour tissue/ 
pleural effusion 
sarcomatoid loss of CDKN2A (7/9); BAP1 point 
mutation (4/9); NF2 loss of function 
(7/9); kataegis (4/9); chromoplexy 
(8/9) 
[49] 
MM2 tumour tissue desmoplastic 
MM3 tumour tissue epithelioid 
MM4 tumour tissue biphasic 
MM5 tumour tissue biphasic 
MM7 tumour tissue epithelioid 
MM8 tumour tissue epithelioid 
MM9 tumour tissue sarcomatoid 
MM10 tumour tissue epithelioid 
MPM 1 tumour tissue  epithelioid NA [60] 
MPM 2 tumour tissue  epithelioid 
MPM 3 tumour tissue  epithelioid 
MPM 4 tumour tissue  biphasic 
MPM 5 tumour tissue  biphasic 
MPM 6 tumour tissue  biphasic 
MPM 7 tumour tissue  sarcomatoid 
MPM 8 tumour tissue  sarcomatoid 
MPM 9 tumour tissue  sarcomatoid 
MESO-3T tumour tissue epithelioid heterozygous loss of NF2 (5/8), 
loss of p16INK4a and p14ARF (7/8), 
structural abnormalities in chr1, 2, 
3, 6, 7 and 9 
[48] 
MESO-7T tumour tissue biphasic 
MESO-8T tumour tissue epithelioid with 
sarcomatoid loci 
MESO-9T tumour tissue epithelioid 
MESO-12T tumour tissue epithelioid 
MESO-14T tumour tissue epithelioid 
MESO-17T tumour tissue epithelioid 
MESO-27T tumour tissue epithelioid 
MM04 pleural biopsy  desmoplastic chromosomal abnormalities 
ranging from 41 to 113; monosomy 
of chr8, 14, 22 (2/5) and 17 (3/5); 
deletion/translocation in chr1, 5, 6 
(epithelioid type) and chr1, 9, 19 
(biphasic type); rearrangement of 
chr1 (5/5) and chr6 (1/5) 
[64] 
MM05 pleural biopsy  biphasic 
MM12 pleural biopsy  biphasic 
MM13 pleural biopsy  biphasic 
MM1081 pleural biopsy  epithelioid 
PF1038 pleural effusion unclassified 
HMM-1 pleural effusion NA NA [57] 
HMM-3 pleural effusion NA NA 
MPM1 pleural effusion sarcomatoid hypotetraploid with a modal chr 79 [55] 
MPM2 pleural effusion epithelioid hypodiploid with a modal chr 40 
MPM3 pleural effusion biphasic hyperdiploid with a modal chr 44 
ACC-MESO-1 tumour tissue epithelioid NF2 mutation (1/4); p16INK4a and 
p14ARF homologous deletion (4/4) 
[65,66]   
ACC-MESO-4 tumour tissue epithelioid 
Y-MESO-8 pleural effusion biphasic 
Y-MESO-9 pleural effusion NA 
Y-MESO-12 pleural effusion NA 
Y-MESO-14 pleural effusion NA 
Y-MESO-21 pleural effusion NA 
Y-MESO-22 pleural effusion NA 
Y-MESO-25 pleural effusion NA 
Y-MESO-26B pleural effusion NA 
Y-MESO-27 pleural effusion NA 
Y-MESO-28 pleural effusion NA 
Y-MESO-29 pleural effusion NA 
Y-MESO-30 pleural effusion NA 
MM-Z03S pleural effusion sarcomatoid both cell lines included 
chromosomal losses of 1q34~qter, 
4, 9p, 10p, 13, 14, 16q, 18, and 22, 
as well as a complex structural 
aberration involving chr17. 
MMZ03E had gains of 3q11q27 
and 5p, while MM-Z03S had gain of 




MES-BR 95 pleural effusion biphasic NA [67]  
MES-CM 98 pleural effusion epithelioid 
MES-CG 98 pleural effusion biphasic 
MES-CE 96 pleural effusion biphasic 
MES-GF 99 pleural effusion biphasic 
MES-MM 98 pleural effusion sarcomatoid 
MES-OC 99 pleural effusion sarcomatoid 
MES-PP 89 pleural effusion sarcomatoid 
JL1 tumour biopsy epithelioid chromosomal deletions and 
translocations; chromosomal 
trisomies and monosomies 
[68] 
DM3 tumour biopsy sarcomatoid 
PJ3 pleural effusion biphasic 
HMMME pleural effusion spindle, round and 
polygonal shape 
aneuploidy [69] 
IST-Mes1 pleural effusion  epithelioid-like monosomy of chr17 (4/4), chr13 
(3/4), chr22 (2/4); 
deletion/translocation of chr6 (4/4), 
chr1 (3/4), chr1 (3/4) 
[70] 
IST-Mes2 pleural effusion  epithelioid-like 
IST-Mes3 pleural effusion  spindle-shaped 
MPP89 pleural effusion  epithelioid-like 
H2596 tumour tissue sarcomatoid deletion, inversion and 
translocation affecting chr1, 3, 6, 9; 
chromosome numbers ranging 
from 34 to 90; abnormalities in 
number of chr3, 4, 5, 9, 11, 14, 15, 
22 
[50] 
H2591 tumour tissue epithelioid 
H2461 tumour tissue epithelioid 
HP-1 pleural effusion biphasic 
HP-2 pleural effusion epithelioid 
H2373 tumour tissue sarcomatoid 
H2452 tumour tissue biphasic 
HP-3 pleural effusion epithelioid 
H2595 tumour tissue epithelioid 
ZL5 pleural effusion biphasic NA [51] 
ZL34 tumour tissue sarcomatoid 
ZL55 tumour tissue epithelioid 
ZL92 pleural effusion not determined 
SPC78 tumour tissue sarcomatoid 
SPC111 pleural effusion biphasic 
SPC212 tumour tissue biphasic 
JU77 pleural effusion spindle-shaped deletion of long arm of chr6 (4/5); 
chromosome 1 rearrangements  
[52] 
LO68 pleural effusion spindle-shaped 
ONE58 pleural effusion spindle-shaped 
NO36 pleural effusion stellate-shaped 
DeH136 pleural effusion pleomorphic 
1/M9K metastasis biphasic deletion of long arm of chr5 (5/6); 
monosomy of chr9 (4/6), chr13 
(3/6) and chr22 (2/6); 
rearrangement of chr1 (3/6) 
[53] 
2/M10K metastasis biphasic 
3/M14K tumour tissue epithelioid 
3/M20 pleural effusion epithelioid 
3/M19 pleural effusion epithelioid 
4/M33K tumour tissue  biphasic 
5/M38K tumour tissue biphasic 
6/M22K tumour tissue biphasic 
6/M19 pleural effusion biphasic 
Mero-25 pleura autopsy biphasic abnormalities in number of ch1, 3, 
6, 9, 12 and 22; loss of chr4 
[54] 
Mero-48a pleura autopsy biphasic 
Mero-72 pleura biopsy biphasic 
Mero-96 pleura biopsy sarcomatoid 
Mero-14 pleural effusion NA 
Mero-41 pleural effusion NA 
Mero-64 pleural effusion NA 
Mero-82 pleural effusion NA 
Mero-83 pleural effusion NA 
Mero-84 pleural effusion NA 
Mero-95 pleural effusion NA 
P31 NA Epithelioid  NA 
VMC6 NA Epithelioid  NA [59][61] 
VMC11 NA Biphasic NA 
VMC12 NA Epithelioid  NA 
VMC14 NA Epithelioid NA 
VMC20 NA Epithelioid  NA 
VMC23 NA Epithelioid  NA 
VMC28 NA Epithelioid NA 
VMC31 NA Epithelioid NA 
VMC33 NA Epithelioid NA 
VMC40 NA Biphasic  NA 
Meso49 NA Epithelioid  NA 
Meso53 NA Biphasic  NA 
Meso62 NA Sarcomatoid NA 
SPC111 NA Biphasic  NA 
SPC212 NA Biphasic  NA 
M38K NA Biphasic  NA 
MM288 NA Epithelioid NA [62] 
MM317 NA Epithelioid NA 
MM404 NA Epithelioid NA 
MM473 NA Epithelioid NA 
MM487 NA Biphasic NA 
MM491 NA Biphasic NA 
MM432 NA Sarcomatoid NA 
MM472 NA Sarcomatoid NA 
H-MESO-1 Tumour Epithelioid Pseudotriploid with 68 
chromosomes 
including multiple abnormalities 
(monosomy, 
translocations, deletion, trisomy, 
and tetrasomy) 
[63] 
 
 
 

